← Back to all trials
Completed
NCT04384367
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
Conditions: Migraine
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 2068
Sponsor: Eurofarma Laboratorios S.A.
Location: Eurofarma Laboratorios S.A São Paulo São Paulo
Summary
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine.
⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
Eligibility Criteria
Inclusion Criteria:
* Patients of both sexes;
* Aged between 18 and 65 years old;
* Capable and willing to give free and informed informed consent in writing;
* Migraine patients with or without aura, according to the International Headache Society (IHS).
Exclusion Criteria:
* Chronic migraine;
* Headache other than migraine (that is, tension-type headache, sinusitis, etc.).
Source: ClinicalTrials.gov (NCT04384367). StuddyBuddy aggregates publicly available trial information.
